巴瑞克替尼(Baricitinib)治疗斑秃一个月费用是多少？

The one-month cost of baricitinib to treat alopecia areata is 240$, 138$, and 1140$ (price before medical insurance), which is mainly related to the version of the drug taken. Different versions of baricitinib have different prices, and the one-month cost of treating alopecia areata is also different.

Baricitinib Specifications

1. Bangladeshi Isida version: 2mg*20 tablets.

2. Bangladesh Yaopin International Edition: 2mg*60 tablets.

3. Domestic original research version: 2mg*28 tablets.

Baricitinib

1. Bangladeshi Isida version: about 160$ per box, with an average price of 8$ per tablet.

2. Bangladesh Yaobin International Edition: about 280$ per box, and the average price per piece is 4.6$.

3. Domestic original research version: the price before medical insurance reimbursement is 1064$, and the average price of one tablet is 38$.

Usage and Dosage

The recommended dose is 2 mg, taken once a day. If response to treatment is insufficient, increase to 4 mg.

One-month dosage for treating alopecia areata

Based on 30 days per month, baricitinib requires 60 mg, which is 30 tablets, for one month to treat alopecia areata.

One month’s cost of treating alopecia areata

1. Bangladesh Isida version:

The specific cost is 30*8=240$. To take more than 10 tablets per box, you need to purchase 2 full boxes. The cost of purchasing medicine is: 2*160=320$.

2. Bangladesh Yaopin International Edition:

The specific cost is 30*4.6=138$, you need to buy 1 full box, and the drug purchase fee is 280$.

3. Domestic original research version:

The specific cost before medical insurance reimbursement is 30*38=1140$. To take more than 2 tablets per box, you need to purchase 2 whole boxes. The cost of purchasing medicine is: 2*1064=2128$.

The price after medical insurance reimbursement will be slightly cheaper, and the reimbursement ratio may be 50% or 70%. The reimbursement policy and reimbursement ratio are different in each region, and the specific price after medical insurance reimbursement will also be different. It is recommended that the local medical insurance department give priority.

Indications

1. Rheumatoid arthritis.

2. Novel coronavirus infection.

3. Alopecia areata.

Results of baricitinib in the treatment of alopecia areata

Research background

The Janus kinase (JAK) inhibitor baricitinib has been shown to be effective in severe alopecia areata (AA) over 36 weeks.

Purpose of the study

In two phase III trials, the efficacy and safety of baricitinib in adult AA patients with ≥50% scalp alopecia were evaluated through 52 weeks of continuous treatment.

Study Methods

Patients in the BRAVE-AA1 (n=465) and BRAVE-AA2 (n=390) arms who were randomized to receive baricitinib at baseline maintained their treatment assignment at Week 52. Efficacy outcomes included the proportion of patients with a Severe Hair Loss Tool (SALT) score of ≤20 points (≤20% scalp hair loss).

Study results

Over 52 weeks, the response rate of hair regrowth increased. Among patients treated with 4 mg and 2 mg baricitinib, 40.9%, 21.2%, and 36.8%, 24.4% of patients in the BRAVE-AA1 group and BRAVE-AA2 group achieved a SALT score ≤20 at week 52.

The most common treatment-emergent adverse events during treatment include upper respiratory tract infection, headache, nasopharyngitis, acne, urinary tract infection, and increased creatine phosphokinase

Research conclusion

The efficacy of baricitinib in adults with severe aplastic anemia continued to improve over 52 weeks, suggesting that long-term treatment may be necessary to observe maximal clinical benefit.

Summary

There are many different versions of Baricitinib. When treating alopecia areata, you can choose the appropriate price and version of Baricitinib according to your own needs, which can reduce the burden of treatment.

References:

Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1. PMID: 36855020; PMCID: PMC9974384.

Related hot article recommendations: